News & Press Releases

Lexology PRO quoted Mintz Member Jacob Hupart in an article about a status report the SEC filed, asking the Eight Circuit Court of Appeals to decide whether its proposed climate disclosure rule is legal. The SEC declined to confirm whether it plans to implement the regulation.

In a recent article, Communications Daily recognized Paul Abbott's return to Mintz as Of Counsel in the firm's Technology, Communications & Media Practice. He returned to Mintz after nearly 10 years as vice president of local government affairs and franchising at Charter Communications.

Life Sciences International Chair Cheryl Reicin recently joined the Scrip M&A Podcast to share insights on the evolving landscape of biopharmaceutical mergers and acquisitions. In the episode, Cheryl highlights an uptick in pre-M&A activity, as major pharmaceutical companies increasingly leverage license and option agreements to strengthen their pipelines and product portfolios while positioning themselves for potential future acquisitions. 

The Deal quoted Mintz Member Alexandra Gallo-Cook in an article examining the complexity and uncertainty that has recently characterized antitrust litigation. The article discusses how states are seizing the moment with legislatures bypassing federal enforcers with proposals that will reshape how mergers are vetted.

San Francisco Office Managing Member Stephen Osborn was featured in CoStar discussing Mintz’s upcoming relocation to a 29,000 square foot office on the 30th floor of 525 Market Street in downtown San Francisco. In the article, Steve shared insights into the decision-making process behind the move, emphasizing the importance of selecting a location that clients and employees would want to spend time in.

Mintz Member Rachel Alexander shared insights with Bloomberg Law for an article about how employers are increasingly challenging state laws regulating pharmacy benefit managers (PBM). The piece focuses on the Supreme Court’s recent decision not to review Oklahoma’s Patient’s Right to Pharmacy Choice Act, which the Tenth Circuit had struck down for violating ERISA. While the ruling applies only to the six states under the Tenth Circuit, it may influence similar cases nationwide.